Loading...

LEXX LEXARIA BIOSCIENCE CORP Other Situations 8-K Filing

LXR

LXX

LEXARIA BIOSCIENCE CORP

(LEXX)

2024 8-K

Show Summary

Show Summary

Product Expansion

Equity Offerings

Sales Agreement Update

Shareholder Meeting

Management Change

Project Agreement

Director Nominations

Management Change

Stock Sale Agreement

Resignation of CFO and Init...

Warrant Exercise Agreement

Annual Shareholder Meeting

Amendment of Material Defin...

Appointment of CFO

FDA Approval for Clinical T...

Securities Purchase Agreement

IND Application for Hyperte...

Regulation FD Disclosure

Compliance and Warrant Exer...

Shareholder Meeting and Oth...

Securities Purchase Agreement

Licensing Amendment and New...

New Product Launches

Management Changes

Entry into a Material Defin...

Investment Offering

Annual Shareholder Meeting

Regulation FD Disclosure

External Links:

Lexaria Bioscience submitted its IND application for a phase 1b hypertension clinical trial with the FDA, which will be an important milestone for the company's DehydraTECH technology.

AI Assistant

LEXARIA BIOSCIENCE CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.